spacer
The Healthcare Sales & Marketing Network celebrates 22 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Angiox 

 HSMN NewsFeed - 30 Oct 2013
The Medicines Company's EUROMAX Trial of Angiox(R) (Bivalirudin) in Heart Attack Meets All Prespecified Endpoints
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 28 Aug 2012
Latest European Heart Attack Treatment Guidelines Recommend Angiomax(R)/Angiox(R) (Bivalirudin) Over Heparin
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 1 Dec 2009
The Medicines Company Receives European Approval for Angiox(R) (Bivalirudin) for Use in Heart Attack Patients Undergoing Emergency Heart Procedures
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 13 May 2009
The Medicines Company Discontinues Phase 3 CHAMPION Clinical Trial Program of Cangrelor
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 5 Aug 2008
The Medicines Company Acquires CU-2010 and Curacyte Discovery GmbH
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 29 Mar 2008
Angiomax Demonstrated Improved Outcomes in Acute Heart Attack Patients Undergoing Primary Angioplasty Independent of Individual Risk Factors
Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 4 Feb 2008
Steven Steinhubl, MD, Joins The Medicines Company as Global Vice President, Thrombosis
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Jan 2008
The Medicines Company's Angiox(R) Receives European Authorization for Expanded Use in Patients with Acute Coronary Syndromes (ACS)
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 7 Jan 2008
James Ferguson, MD Joins The Medicines Company as Vice President, Global Medical, Surgical and Critical Care
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Dec 2007
Journal of the American Medical Association (JAMA) Publishes One-Year ACUITY Trial Results
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 24 Oct 2007
Angiomax(R) / Angiox(R) (bivalirudin) Significantly Improved Net Outcomes in Heart Attack Patients
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 23 Oct 2007
Cleviprex(TM) (Clevidipine Butyrate) Rapidly Reduced Blood Pressure and Maintained Control in Study of Patients with Acute Hypertension
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 15 Oct 2007
Improved Perioperative Blood Pressure Control Associated with Reduced Risk of Kidney Dysfunction in Cardiac Surgery Patients
Biopharmaceuticals Cardiology Surgery
 HSMN NewsFeed - 24 Sep 2007
FDA Accepts sNDA for Expanded Use of Angiomax(R) (bivalirudin)
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 14 Sep 2007
FDA Accepts NDA Filing for Cleviprex(TM) (Clevidipine Butyrate Injectable Emulsion) for the Treatment of Acute Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 2 Sep 2007
Angiox(R) (Bivalirudin) Alone Reduced Early Bleeding and Resulted in Similar One-Year Mortality Compared to Heparins Plus GP IIb/IIIa Combination Therapy in ACS Patients Undergoing Angioplasty
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 7 Aug 2007
The Medicines Company Submits Angiomax(R) (Bivalirudin) sNDA to Expand Label to Include ACUITY Data
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 2 Jul 2007
The Medicines Company Reacquires Angiox(R) (Bivalirudin) Rights in Europe from Nycomed
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 12 Mar 2006
Angiomax(R) (bivalirudin) Monotherapy Superior to Heparins Plus GP IIb/IIIa Combination for Net Clinical Outcome in ACUITY Trial
Biopharmaceuticals Cardiology
Return to NewsFeed  

 Additional items found! 3

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 3 additional stories matching:
Angiox
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.